Mylan Inc. clinical trials

Acquired by Viatris Inc., Nov 16, 2020 · source ↗

The registry lists 44 studies whose lead sponsor is Mylan Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 30, 2025.

Studies

Recruiting first, then most recently updated. Showing 44 of 44. All Viatris Inc. studies →

• Study to Evaluate the Effectiveness of Legalon®CompletedNCT05051527

  Sponsor listed in the registry: Mylan Inc. · First submitted after Mylan Inc. became part of Viatris Inc.

• Observational Study to Evaluate the Actual Use and Effectiveness of Dymista® Nasal Spray in Asian PatientsCompletedNCT05158972

  Sponsor listed in the registry: Mylan Inc. · First submitted after Mylan Inc. became part of Viatris Inc.

• Observation of the Effects of Guideline-driven Lifestyle Interventions, Including Use of a Red-yeast Based NutraceuticalCompletedNCT05000541

  Sponsor listed in the registry: Mylan Inc. · First submitted after Mylan Inc. became part of Viatris Inc.

• Observational Study to Evaluate the Actual Use of Elidel® in Chinese Patients With Mild to Moderate Atopic DermatitisCompletedNCT04976868

  Sponsor listed in the registry: Mylan Inc. · First submitted after Mylan Inc. became part of Viatris Inc.

• A Dose Ranging Vehicle Controlled Study to Determine the Safety and Efficacy of Permethrin Foam, 5% and Permethrin Foam, 4% for the Treatment of ScabiesCompletedNCT02094716Phase 2

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control GroupTerminatedNCT00634166Phase 4

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• Dose-Response Study of MR-107A-01 in The Treatment of Post-Surgical Dental PainCompletedNCT04571515Phase 2

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• A Survey on Efficacy and Safety in Patients With EndometriosisCompletedNCT02921763

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• Special Investigation of LipaCreon on Long-term Use in Patients With Pancreatic Exocrine InsufficiencyCompletedNCT01427725

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic FibrosisCompletedNCT01427712

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• REVIparin-BRIDging-in a General Practice Setting in GErmanyTerminatedNCT02579122

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• Omacor Plus Standard Therapies In Post Myocardial Infarction (MI) Subjects Evaluation: The OPTIMISE Observational StudyCompletedNCT01632878

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• Special Investigation of Clarith/Klaricid in Patients With Non-tuberculous Mycobacterial Pulmonary InfectionsCompletedNCT01097005

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• Abacavir, Dolutegravir and Lamivudine Dispersible Tablets (60 mg/5 mg/30 mg)CompletedNCT05030025Early Phase 1

  Sponsor listed in the registry: Mylan Inc. · First submitted after Mylan Inc. became part of Viatris Inc.

• Phase I - Pharmacokinetic Comparability Study in Healthy Male VolunteersCompletedNCT02469987Phase 1

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• Observational Study in Cystic Fibrosis Patients Using TOBI® PODHALER® or Other FDA Approved Inhaled Antipseudomonal Antibacterial DrugsCompletedNCT02449031

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• Evaluation of Pain Associated With the Removal of Wound Dressing During Care of Venous Leg Ulcer. Comparison of the Efficacy and Safety of Two Dressings Urgotul and TulleGrasCompletedNCT02104180Not applicable

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• Comparison of Efficacy on Healing, and Safety of Two Dressings Urgotul and TulleGras MS on Surgical Acute Wounds.CompletedNCT02322710Not applicable

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• MYL-1401A Efficacy and Safety Comparability Study to Humira®CompletedNCT02714322Phase 3

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• Adalimumab PK Bioequivalence Study to EU and US Sourced HumiraCompletedNCT02472912Phase 1

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• Therapeutic Equivalence and Safety of Two Econazole Nitrate Cream, 1% Products in Tinea PedisCompletedNCT03129321Phase 3

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic DermatitisCompletedNCT03107611Phase 3

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• Mylan Insulin Glargine StudyCompletedNCT03376789Phase 3

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)CompletedNCT02227862Phase 3

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) PatientsCompletedNCT02666430Phase 3

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)CompletedNCT02227875Phase 3

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo CapsulesCompletedNCT03502070Phase 4

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• Mylan Insulin Aspart StudyCompletedNCT03760068Phase 3

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic ImpairmentCompletedNCT02581592Phase 1

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• Pharmacokinetics of TD-4208 in Patients With Severe Renal ImpairmentCompletedNCT02578082Phase 1

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02459080Phase 3

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02040792Phase 2

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• 7 Days of TD-4208 in Subjects With Chronic Obstructive Pulmonary DiseaseCompletedNCT01704404Phase 2

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02109172Phase 2

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02518139Phase 3

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02512510Phase 3

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPDCompletedNCT03573817Phase 3

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT03064113Phase 2

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male SubjectsCompletedNCT02772159Phase 1

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPDCompletedNCT03095456Phase 3

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• Thorough QT (TQT) Study of TD-4208 in Healthy SubjectsCompletedNCT02820311Phase 1

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• Pharmacokinetic / Pharmacodynamic Study Comparing MYL-1401H, EU-sourced Neulasta and US-licensed NeulastaCompletedNCT02479646Phase 1

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• Efficacy and Safety Study With MYL-1401H and NeulastaCompletedNCT02467868Phase 3

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.

• Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca.CompletedNCT02472964Phase 3

  Sponsor listed in the registry: Mylan Inc. · First submitted before Mylan Inc. became part of Viatris Inc.